ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
2026 ARDC Annual Survey is now open!

The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your interaction with the ARDC and use of our national research infrastructure and services. The survey will take approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure services including Reasearch Link Australia.

We will use the information you provide to improve the national research infrastructure and services we deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS) program.

Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.

Complete the 5 min survey now by clicking on the link below.

Take Survey Now

Thank you.

  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Australian State/Territory : WA
Field of Research : Pharmacology and Pharmaceutical Sciences
Status : Closed
Clear All
Filter by Field of Research
Pharmacology and Pharmaceutical Sciences (4)
Basic Pharmacology (1)
Colloid and Surface Chemistry (1)
Environmental And Occupational Health And Safety (1)
Nanomedicine (1)
Pharmaceutical Sciences (1)
Pharmaceutical Sciences And Pharmacy (1)
Toxicology (Incl. Clinical Toxicology) (1)
Filter by Socio-Economic Objective
Combined operations (1)
Diabetes (1)
Human Pharmaceutical Treatments (e.g. Antibiotics) (1)
Occupational health (excl. economic development aspects) (1)
Filter by Funding Provider
Australian Research Council (3)
National Health and Medical Research Council (1)
Filter by Status
Closed (4)
Filter by Scheme
ARC Future Fellowships (1)
Discovery Projects (1)
Linkage Projects (1)
NHMRC Project Grants (1)
Filter by Country
Australia (4)
Filter by Australian State/Territory
WA (4)
VIC (2)
ACT (1)
NSW (1)
QLD (1)
SA (1)
  • Researchers (9)
  • Funded Activities (4)
  • Organisations (3)
  • Funded Activity

    Examination Of The Molecular Pharmacology Of Anthracyclines Induced Via Their Interaction With Iron

    Funder
    National Health and Medical Research Council
    Funding Amount
    $618,401.00
    Summary
    Anthracyclines are highly effective anti-cancer drugs, but their use is limited by toxic effects on the heart. This is thought to be due to these drugs directly binding iron (Fe). Indeed, we showed that anthracyclines induced marked changes in the way heart cells utilise Fe (DR1-3, 38; Mol. Pharmacol. 2002, 2003, 2004, 2005). We were the first to show that anthracyclines prevent Fe release from the criticial Fe storage protein ferritin. This prevents the use of Fe for vital processes eg. DNA and .... Anthracyclines are highly effective anti-cancer drugs, but their use is limited by toxic effects on the heart. This is thought to be due to these drugs directly binding iron (Fe). Indeed, we showed that anthracyclines induced marked changes in the way heart cells utilise Fe (DR1-3, 38; Mol. Pharmacol. 2002, 2003, 2004, 2005). We were the first to show that anthracyclines prevent Fe release from the criticial Fe storage protein ferritin. This prevents the use of Fe for vital processes eg. DNA and haem synthesis. Hence, this effect probably contributes to the cytotoxic activity of anthracyclines on the heart. We showed that novel drugs developed in my lab that bind Fe called chelators show high activity in animals (DR4) and prevent anthracycline-mediated Fe accumulation in ferritin. Importantly, Fe chelators have been shown to inhibit anthracycline-mediated cardiotoxicity. Indeed, the clinically used cardioprotective agent, ICRF-187, is actually an Fe chelator (5, DR6). However, ICRF-187 is not totally successful in terms of its cardioprotective effects and can cause myelosuppression (5, DR6). While the clinically used chelator, desferrioxamine (DFO), can prevent anthracycline-mediated cardiotoxicity, its poor membrane permeability limits its effectiveness. Our chelators are highly permeable and overcome the disadvantages of DFO (DR4). Thus, they are vital to examine for preventing anthracycline-mediated cardiotoxicity. In this proposal we will examine the changes in Fe metabolism induced by anthracyclines and test the hypothesis that novel Fe chelators may prevent the cardiotoxicity of these agents. We also aim to be the first to assess if preparation of anthracyclines which cannot bind iron prevents their cardiotoxicity. This will be done by preparing metal complexes of these drugs which prevent Fe-binding eg. anthracycline-zinc complexes. These studies are important for the development of less cardiotoxic forms of these very useful anti-tumour agents.
    Read more Read less
    More information
    Funded Activity

    ARC Future Fellowships - Grant ID: FT120100697

    Funder
    Australian Research Council
    Funding Amount
    $796,367.00
    Summary
    Light-responsive nanomaterials as nanomedicines: new approaches to treating macular degeneration, cancer and other critical unmet therapeutic needs. Nanotechnology is enabling new medicines for the treatment of important diseases such as cancer and macular degeneration. This project will investigate novel nanomaterials for the development of new highly effective medicines that can be controlled after administration, leading to reduced side effects and increased convenience for patients.
    More information
    Funded Activity

    Linkage Projects - Grant ID: LP0453964

    Funder
    Australian Research Council
    Funding Amount
    $180,000.00
    Summary
    Micro- and nano-particulate delivery systems for chemical and biological weapons: physical characterisation and risk assessment. Inert solid powder has been used as a carrier for chemical and biologically-active agents to increase their effectiveness in a range of applications such as chemical weapons, pesticides and insecticides. The aim of this research is to determine the influence of the physical characteristics of particulate delivery systems on their ability to deliver potentially toxic s .... Micro- and nano-particulate delivery systems for chemical and biological weapons: physical characterisation and risk assessment. Inert solid powder has been used as a carrier for chemical and biologically-active agents to increase their effectiveness in a range of applications such as chemical weapons, pesticides and insecticides. The aim of this research is to determine the influence of the physical characteristics of particulate delivery systems on their ability to deliver potentially toxic substances to exposed skin and through protective clothing. This data will provide the first step in the design and development of effective protective clothing/products and safety protocols to safeguard the health of Australians involved in the defence of Australia.
    Read more Read less
    More information
    Funded Activity

    Discovery Projects - Grant ID: DP120101297

    Funder
    Australian Research Council
    Funding Amount
    $270,000.00
    Summary
    Investigating the functional interaction between vasopressin and angiotensin receptors. Kidney disease resulting from diabetes is a major health issue for Australians, and indigenous Australians in particular. This project aims to enable improved therapies to be developed, as well as better inform doctors regarding the use of potential combinations of existing pharmaceuticals to treat this condition.
    More information

    Showing 1-4 of 4 Funded Activites

    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback